Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
| Horizon | Bear case (−1σ) | Base case | Bull case (+1σ) |
|---|---|---|---|
| 1 Month | $130.85 (-13.9%) | $152.02 | $176.60 (+16.2%) |
| 3 Months | $117.25 (-22.9%) | $152.02 | $197.08 (+29.6%) |
| 6 Months | $105.30 (-30.7%) | $152.02 | $219.46 (+44.4%) |
| 12 Months | $90.44 (-40.5%) | $152.02 | $255.51 (+68.1%) |